Non disponible en dehors du Royaume-Uni et de l'Irlande
Biochem/physiol Actions
CE-178253 is an extremely potent and selective CB1 antagonist with sub-nanomolar potency. In binding assays, CE-178253 has a 0.33 nM Ki for human CB1, vs. a Ki of > 10 mM for human CB2.
Features and Benefits
This compound is featured on the Cannabinoid Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
Legal Information
Pfizer is a registered trademark of Pfizer, Inc.
Sold for research purposes under agreement from Pfizer Inc.
Other Notes
This compound was developed by Pfizer for Neuroscience research. To learn more about Sigma′s partnership with Pfizer and view other authentic, high-quality Pfizer compounds, visit sigma.com/bsm-pfizer.To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Packaging
5, 25 mg in glass bottle
Ce produit répond aux critères suivants pour être admissible aux récompenses suivantes :